Number of subjects experiencing dose limiting toxicity (DLT) Up to Day 28 of Cycle 1 [clinicaltrials_resource:85a949c6b6e3142c73e00566b33a1aca]
TH-302 will be administered at a dose ranging from 170-340 milligram per square meter (mg/m^2) as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Number of subjects experiencing dose limiting toxicity (DLT) Up to Day 28 of Cycle 1 [clinicaltrials_resource:85a949c6b6e3142c73e00566b33a1aca]
TH-302 will be administered at a dose ranging from 170-340 milligram per square meter (mg/m^2) as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Bio2RDF identifier
85a949c6b6e3142c73e00566b33a1aca
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:85a949c6b6e3142c73e00566b33a1aca
measure [clinicaltrials_vocabulary:measure]
Number of subjects experiencing dose limiting toxicity (DLT)
time frame [clinicaltrials_vocabulary:time-frame]
Up to Day 28 of Cycle 1
description
TH-302 will be administered at ...... oxicity or subject withdrawal.
identifier
clinicaltrials_resource:85a949c6b6e3142c73e00566b33a1aca
title
Number of subjects experiencing dose limiting toxicity (DLT) Up to Day 28 of Cycle 1
@en
type
label
Number of subjects experiencin ...... 949c6b6e3142c73e00566b33a1aca]
@en